ElsaLys Biotech designs and develops "best-in-disease" therapeutic antibodies targeting oncology and ophthalmology indications. The company focuses on innovative targets involved in immune response, angiogenesis, survival, proliferation, adhesion and migration. Its pipeline includes three proprietary antibodies across four development programmes and relies on an academic network and an in-house R&D platform. Current development priorities include an anti-CD160 programme for ophthalmology (advancing through toxicology) and oncology-focused candidates including anti-CD160 and anti-TYRO3. The recent financing is intended to support completing preclinical proof-of-concept and the next phase of programme development. Founded in 2013, the company is led by Dr Christine Guillen, has a nine-person team, a head office in Lyon Gerland bio-district and laboratories in the Illkirch‑Graffenstaden Science and Technology Park. ElsaLys Biotech specializes in the development of therapeutic monoclonal antibodies, converting first-in-class academic targets into drug candidates. Its current portfolio comprises four novel projects sourced from partners including EFS, Curie Institute, the Tumor Institute of Turin and SATT‑Sud Est. In the short term the company will advance antibodies against targets from academic collaborators to characterized drug candidates with robust in vivo proof of concept. Further clinical development is planned through industrial partnerships. The team is composed of co-founders from Transgene, and company leadership includes CEO Dr Jean‑Yves Bonnefoy and COO Dr Christine Guillen. ElsaLys is based in Lyon and Illkirch‑Graffenstaden and benefits from cluster environments such as Lyon Biopole and Alsace BioValley.

Total raised

$6M

Funding rounds

2

Latest round

Equity

Latest activity

Nov 2015